engleski

The level of cathepsin D and plasminogen activator inhibitor type 1 in normal, benign and malignant ovarian tissues.

Among gynaecological malignancies, ovarian cancer has been the major cause of death, because it is usually presented in advances clinical stage, with extensive intraabdominal metastasis and the unavoidable development of resistance to chemotherapy. Research continues along several fronts in an attempt to improve the diagnosis and prognosis of women with ovarian cancer. The aim of the present study was to determine the concentrations of cathepsin D (Cath D) and plasminogen activator inhibitor type 1 (PAI-1) in normal, benign and malignant ovarian tissues, and to asses relationship between Cath D and PAI-1 content and some clinical and pathohistological parameters. Cath D and PAI-1, two tumor markers for invasion and metastasis, were analysed in 35 samples: 10 normal ovarii, 10 benign, 10 primary malignant and 5 metastatic ovarian tumors. Their levels were quantified using immunoradiometric ELSA-Cath D assay and commercial IMUBINDR ELISA immunoassay, respectively. The concentrations of Cath D were significantly higher in malignant (32.89ą14.26 pmol/mg protein ) and metastatic (31.42 ą10.24 pmol/mg protein), than in normal (13.68ą4.03 pmol/mg protein) and benign (17.89ą13.13 pmol/mg protein) ovarian tissues. There was no statistical differences in the concentrations of PAI-1 between normal, benign , malignant and metastatic tumor specimens. The concentration of Cath D as well as PAI-1 did not correlate to age of patients, menopausal status, parity, GOG risk group, clinical stage or pathohistological grading. In conclusion, concentrations of Cath D ( but not PAI-1) were significantly increased in malignant and metastatic ovarian tumor tissues when compared to normal and benign ovarian tumor samples; they were independent from pathohistological and clinical parameters.

cathepsin D; plasminogen activator inhibitor; ovarian tissue; tumor

nije evidentirano